FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)														
1. Name and Address of Reporting Person * Crescenzo Andrew R.				2. Issuer Name and Ticker or Trading Symbol ENZO BIOCHEM INC [ENZ]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
(Last) (First) (Middle) C/O ENZO BIOCHEM, INC, 527 MADISON AVENUE				3. Date of Earliest Transaction (Month/Day/Year) 01/22/2009						X Officer (give title below) Other (specify below) Senior VP of Finance						
(Street) NEW YORK, NY 10003				4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person						
(City) (State) (Zip)				Table I - Non-Derivative Securities Acquire						ired, Disp	red, Disposed of, or Beneficially Owned					
1.Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, any (Month/Day/Yea	(Instr. 8)		ction	4. Securities Acqu (A) or Disposed of (Instr. 3, 4 and 5)		of (D)	Beneficia	ant of Securities ally Owned Following d Transaction(s) and 4)		\ /	Beneficial Ownership	
						(Code	V	Amoun	(A) or (D)	Price				or Indirect (I) (Instr. 4)	(Instr. 4)
Common Stock 01		01/22/2009				A		9,000	A	<u>(1)</u>	21,803	803 (2)		D		
			Table II -	Derivativ			cquire	conta the fo	ained in orm dis sposed o	n this for splays a of, or Ben	rm are curre	e not requently valid	OMB conf	spond unle trol numbe	ss	1474 (9-02)
	Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Da any	4. te, if Transaction Code Year) (Instr. 8)		5. Num of Deri Secu Acqui (A) of Disp of (I (Inst	5. Number a		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. T Am Und Sec	Fitle and count of derlying urities str. 3 and	Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Owners Form of Derivati Security Direct (I or Indire	Beneficial Ownership (Instr. 4)
				Code	ode V	(A)	(D)	Date Exerc		Expiration Date	n Titl	Amount or e Number of Shares				

Reporting Owners

B 41 0 N 4	Relationships							
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
Crescenzo Andrew R. C/O ENZO BIOCHEM, INC 527 MADISON AVENUE NEW YORK, NY 10003			Senior VP of Finance					

Signatures

/s/ Andrew Crescenzo	01/26/2009			
**Signature of Reporting Person	Date			

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a)
- (1) Andrew Crescenzo was granted 9,000 shares of restricted Common Stock on January 22, 2009.
- (2) This number includes 803 shares of Common Stock held in the Company's 401(k) plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.